Zhao Yi Peng, Fine Barry M
Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Cells. 2025 Sep 6;14(17):1393. doi: 10.3390/cells14171393.
Heart disease remains a leading cause of morbidity and mortality worldwide, necessitating the development of in vivo models for therapeutic development. Advances in biomedical engineering in the past decade have led to the promising rise of human-based engineered cardiac tissues (hECTs) using novel scaffolds and pluripotent stem cell derivatives. This has led to a new frontier of human-based models for improved preclinical development. At the same time, there has been significant progress in elucidating the importance of the immune system and, in particular, macrophages, particularly during myocardial injury. This review summarizes new methods and findings for deriving macrophages from human pluripotent stem cells (hPSCs) and advances in integrating these cells into cardiac tissue. Key challenges include immune cell infiltration in 3D constructs, maintenance of tissue architecture, and modeling aged or diseased cardiac microenvironments. By integrating immune components, hECTs can serve as powerful tools to unravel the complexities of cardiac pathology and develop targeted therapeutic strategies.
心脏病仍然是全球发病和死亡的主要原因,因此需要开发用于治疗开发的体内模型。过去十年中生物医学工程的进展促使使用新型支架和多能干细胞衍生物的基于人类的工程心脏组织(hECTs)有望兴起。这开创了用于改进临床前开发的基于人类的模型的新领域。与此同时,在阐明免疫系统尤其是巨噬细胞的重要性方面取得了重大进展,特别是在心肌损伤期间。本综述总结了从人类多能干细胞(hPSCs)中获取巨噬细胞的新方法和新发现,以及将这些细胞整合到心脏组织中的进展。关键挑战包括三维构建体中的免疫细胞浸润、组织结构的维持以及对衰老或患病心脏微环境的建模。通过整合免疫成分,hECTs可以作为强大的工具来揭示心脏病理学的复杂性并制定靶向治疗策略。